Research programme: anti-RSV monoclonal antibodies - Medarex/AstraZeneca
Alternative Names: Anti-RSV monoclonal antibodies research programme - Medarex/AstraZenecaLatest Information Update: 09 Aug 2021
At a glance
- Originator Medarex; MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)
- 29 Sep 2004 This programme is still in active development
- 27 Jul 2000 New profile